Drug intelligence / Profile preview

cefazolin + tobramycin + gentamicin

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Ophthalmic, Intravenous, Intramuscular

Overview

A combination of three antibiotics including cefazolin (a first-generation cephalosporin) and two aminoglycosides (tobramycin and gentamicin). This combination is not a standard commercial formulation but may be used in specific clinical scenarios where broad-spectrum coverage is needed. Cefazolin inhibits bacterial cell wall synthesis, while aminoglycosides like tobramycin and gentamicin work by binding to bacterial ribosomes and inhibiting protein synthesis. The combination may provide synergistic bactericidal activity against certain bacterial strains.

Targets

PBP (Penicillin-binding protein family)16S rRNA (16S ribosomal RNA)Bacterial Ribosome

Beyond the preview

Go deeper on cefazolin + tobramycin + gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefazolin + tobramycin + gentamicin.

Explore the full profile